Abstract
Few studies have evaluated concordance between different commercially available programmed death-ligand 1 (PD-L1) assays. Tissue from 32 patients with metastatic renal cell carcinoma and 18 patients with metastatic urothelial carcinoma were assessed by 2 different PD-L1 assays each and found 91% and 94% concordance between assays, respectively. These results suggest strong concordance and similar performance characteristics across PD-L1 assays.
Original language | English (US) |
---|---|
Pages (from-to) | 509-513 |
Number of pages | 5 |
Journal | Clinical Genitourinary Cancer |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2020 |
Externally published | Yes |
Keywords
- Biomarkers
- Dako
- Immunohistochemistry
- Immunotherapy
- Programmed death receptor-1
ASJC Scopus subject areas
- Oncology
- Urology